Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.

CONCLUSIONS: At its current price, teduglutide does not provide a cost-effective addition to transplantation in the treatment of pediatric short bowel syndrome. Further work should look to identify cost-reducing strategies, including alternative dosing regimens. PMID: 33021637 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33021637?dopt=Abstract

Source: The American Journal of Clinical Nutrition - October 6, 2020 Category: Nutrition Authors: Raghu VK, Rudolph JA, Smith KJ Tags: Am J Clin Nutr Source Type: research